Lantheus Holdings, Inc (LNTH)

Etorro trading 970x250

About Lantheus Holdings, Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts. Address: 331 Treble Cove Road, North Billerica, MA, United States, 01862

Lantheus Holdings, Inc News and around…

Latest news about Lantheus Holdings, Inc (LNTH) common stock and company :

Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022
22 Nov, 2021 Yahoo! Finance

PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that the Centers for Medicare & Medicaid Serv

Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings
17 Nov, 2021 Yahoo! Finance

NORTH BILLERICA, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today poster presentations featuring PYLARIFY® (piflufolastat F 18) data from the Company’s Phase 3 CONDOR study at the upcoming Scientific Assembly and Annual Meeti

Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
16 Nov, 2021 Yahoo! Finance

NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the 4th Annual Evercore ISI HealthCONx Conference at 1:00 p.m. ET on Tuesday, November 30. To a

How Good Are Lantheus Holdings's Earnings? | Return On Capital Employed
08 Nov, 2021 FinancialContent

According to Benzinga Pro data, during Q3, Lantheus Holdings (NASDAQ:LNTH) posted sales of $102.07 million. Earnings were up 46.5%, but ...

Lantheus Holdings, Inc (LNTH) Q3 2021 Earnings Call Transcript
07 Nov, 2021 FinancialContent

LNTH earnings call for the period ending September 30, 2021.

Lantheus Holdings (LNTH) Tops Q3 Earnings and Revenue Estimates
04 Nov, 2021 Yahoo! Finance

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 33.33% and 5.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
04 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral ...

Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results
04 Nov, 2021 Yahoo! Finance

Worldwide revenue of $102.1 million for the third quarter 2021, representing an increase of 15.3% from the prior year periodGAAP net loss of $13.4 million for the third quarter 2021, compared to GAAP net loss of $6.4 million in the prior year periodGAAP fully diluted net loss of $0.20 for the third quarter 2021, compared to GAAP fully diluted net loss of $0.10 in the prior year period; adjusted fully diluted EPS of $0.08 for the third quarter 2021, compared to adjusted fully diluted EPS of $0.04

Implied VIOO Analyst Target Price: $240
01 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P Small-Cap 600 ETF (VIOO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $240.04 per unit.

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct, 2021 FinancialContent

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...

Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern Time
21 Oct, 2021 Yahoo! Finance

NORTH BILLERICA, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021, to discuss its financial and operating results for the third quarter of 2021. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 6775813. A live webcast will also be availa

Relative Strength Alert For Lantheus Holdings
18 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Analysts Anticipate SPSM To Hit $50
29 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— Portfolio S&P 600 Small Cap ETF (SPSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $49.97 per unit.

Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer
13 Sep, 2021 FinancialContent

Lantheus’ product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer

Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment
13 Sep, 2021 FinancialContent
Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting
10 Sep, 2021 FinancialContent
Lantheus Holdings to Present at Upcoming Investor Conferences
02 Sep, 2021 FinancialContent
Return on Capital Employed Overview: Lantheus Holdings
04 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Lantheus Holdings (NASDAQ:LNTH) brought in sales totaling $101.06 ...

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer
29 Jul, 2021 FinancialContent

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation). Clinicians will have the option to utilize aPROMISE with PYLARIFY® (piflufolastat F 18) to increase the efficiency and reproducibility of their PSMA PET/CT assessments. PYLARIFY was recently approved by the FDA and is the first and only commercially available PSMA-targeted PET imaging agent for prostate cancer.

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer
29 Jul, 2021 Yahoo! Finance

NORTH BILLERICA, Mass., July 29, 2021--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation). Clinicians will have the option to utilize aPROMISE with PYLARIFY® (piflufolastat F 18) to increase the efficiency and reproducibility of their PSMA PET/CT assessment

Lantheus Holdings, inc (LNTH) Q2 2021 Earnings Call Transcript
28 Jul, 2021 FinancialContent

LNTH earnings call for the period ending June 30, 2021.

Lantheus Stock Gains As Q2 Earnings Surpasses Expectations; Raises FY2021 Outlook
28 Jul, 2021 FinancialContent

Lantheus Holdings Inc(NASDAQ: LNTH) clocked $101.1 million in sales for Q2 of 2021, beating the consensus of $94.9 million, ...

Lantheus Holdings (LNTH) Q2 Earnings and Revenues Beat Estimates
28 Jul, 2021 Yahoo! Finance

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 120.00% and 6.83%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Lantheus Holdings: Q2 Earnings Insights
28 Jul, 2021 FinancialContent

Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected after the company reported Q2 results. Quarterly ...

Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
28 Jul, 2021 FinancialContent

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today reported financial results for its second quarter ended June 30, 2021.

Earnings Preview: Lantheus Holdings
27 Jul, 2021 FinancialContent

On Wednesday, July 28, Lantheus Holdings (NASDAQ:LNTH) will release its latest earnings report. Decipher the announcement with ...

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
25 Jul, 2021 FinancialContent

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism ...

Analysts Estimate Lantheus Holdings (LNTH) to Report a Decline in Earnings: What to Look Out for
21 Jul, 2021 Yahoo! Finance

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively
20 Jul, 2021 Yahoo! Finance

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Lantheus Holdings, Inc (LNTH) is a NASDAQ Common Stock listed in , ,

970x250